Delivery of genetic therapies to affected tissues is a key challenge to developing new treatments for people with cystic fibrosis. In addition to investing in viral delivery and lipid nanoparticles, the Cystic Fibrosis Foundation is looking at the potential of a relatively new approach to delivery using an exceptionally small synthetic molecule called a polymer nanoparticle.
During the annual event, volunteers advocated for the PASTEUR Act and the HELP Copays Act, two bipartisan pieces of legislation that could have substantial, positive impact on the CF community.
|
3 min read
Two-thirds of people with cystic fibrosis in the U.S. experience debt, food insecurity, or housing issues.
|
4 min read
The Foundation seeks to advance its mission by making improvements in key areas of health equity and outcomes and diverse workforce development.
|
3 min read
The Foundation’s commitment to these principles will continue to be a cornerstone of the Foundation’s work to advance our mission in 2023.
|
4 min read
The Cystic Fibrosis Foundation’s investment will go toward conducting preclinical research on a novel gene delivery vehicle. If successful, this gene delivery method could overcome some of the biggest challenges to delivering a gene therapy into the lung cells of people with cystic fibrosis.
|
2 min read
206 care center directors sign a letter citing clinical consequences if decision moves forward.
|
3 min read
The physical footprint of the Cystic Fibrosis Foundation Therapeutics Lab grew by about a third this year, enabling startup companies and industry scientists to work and learn alongside lab staff.
|
4 min read
The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
|
2 min read
Vertex’s copay assistance changes add an undue burden for people living with an already expensive, challenging lifelong disease.
|
3 min read